Case 6:12-cv-00799-JRG Document 81-9 Filed 10/25/13 Page 1 of 3 PageID #: 2288
`Case 6:12—cv—00799—JRG Document 81-9 Filed 10/25/13 Page 1 of 3 Page|D #: 2288
`
`
`
`
`EXHIBIT G
`
`EXHIBIT G
`
`
`
`
`
`
`

`
`Case 6:12-cv-00799-JRG Document 81-9 Filed 10/25/13 Page 2 of 3 PageID #: 2289
`
`Quick, Stephanie A.
`
`From:
`Sent:
`To:
`Cc:
`Subject:
`
`Jelenchick, Kadie M.
`Wednesday, October 09, 2013 11:15 PM
`Papastavros, Nick; Hansen, Linda E.B.
`Frost, Claudia; Johnson, Jeffrey
`RE: Invensys/Emerson - Infectious Unenforceability Cases
`
`Nick:
`
`
`Yesterday's brief mentions testing and research that was done following the filing of the '742 provisional
`application. Please provide a copy of this testing and research or direct us to where it may be found in Invensys's
`document production.
`
`
`
`Thanks,
`
`
`Kadie M. Jelenchick
`Foley & Lardner LLP
`777 East Wisconsin Avenue
`Milwaukee, WI 53202
`414.319.7324
`kjelenchick@foley.com
`
`From: Papastavros, Nick [Nick.Papastavros@dlapiper.com]
`Sent: Tuesday, October 08, 2013 5:23 PM
`To: Jelenchick, Kadie M.; Hansen, Linda E.B.
`Cc: Frost, Claudia; Johnson, Jeffrey
`Subject: RE: Invensys/Emerson - Infectious Unenforceability Cases
`
`Kadie, 
`
`  
`We can’t at this late stage revise the brief to reflect this, but I will try to drop a footnote and will indicate this in the 
`Certificate of Conference. 
`
`  
`Please let me know if you agree to withdraw the remaining portions of the counterclaim/affirmative defense after 
`reviewing the filing. 
`
`  
`Nick 
`
`  
`From: KJelenchick@foley.com [mailto:KJelenchick@foley.com]
`Sent: Tuesday, October 08, 2013 5:23 PM
`To: Papastavros, Nick; LHansen@foley.com
`Cc: Frost, Claudia
`Subject: RE: Invensys/Emerson - Infectious Unenforceability Cases 
`
`  
`Nick: 
`
`  
`We continue to disagree with Invensys’s assessment of Micro Motion’s infectious unenforceability pleadings.  However, 
`in the interest of avoiding motion practice on this issue, Micro Motion will stipulate to a withdrawal of Paragraphs 73 
`and 95‐96 of the Affirmative Defenses and Paragraphs 37‐38 of the Amended Counterclaims.  Consistent with the 
`Second Amended Docket Control Order, Micro Motion reserves the right to amend its pleadings to renew these 
`allegations at the appropriate time. 
`
`1
`
`

`
`Case 6:12-cv-00799-JRG Document 81-9 Filed 10/25/13 Page 3 of 3 PageID #: 2290
`
`  
`If you would like to discuss this further, please feel free to give me a call. 
`
`  
`Thanks, 
`Kadie M. Jelenchick 
`Foley & Lardner LLP 
`777 East Wisconsin Avenue 
`Milwaukee, Wisconsin 53202 
`414.319.7324 
`kjelenchick@foley.com 
`
`  
`From: Papastavros, Nick [mailto:Nick.Papastavros@dlapiper.com]
`Sent: Tuesday, October 08, 2013 11:22 AM
`To: Hansen, Linda E.B.; Jelenchick, Kadie M.
`Cc: Frost, Claudia
`Subject: FW: Invensys/Emerson - Infectious Unenforceability Cases 
`
`  
`Linda and Kadie, 
`
`  
`Following up on our meet and confer yesterday afternoon, attached are several cases supporting the notion of deficient 
`“infectious unenforceability” pleading, which Invensys contends is the case with respect to Micro Motion’s inequitable 
`conduct defense and counterclaim.  Please let us know if you believe it would be productive to confer further. 
`
`  
`Nick 
`  
`
`  
`Please consider the environment before printing this email.
`
`The information contained in this email may be confidential and/or legally privileged. It has been sent for the sole use of the intended
`recipient(s). If the reader of this message is not an intended recipient, you are hereby notified that any unauthorized review, use, disclosure,
`dissemination, distribution, or copying of this communication, or any of its contents, is strictly prohibited. If you have received this
`communication in error, please reply to the sender and destroy all copies of the message. To contact us directly, send to
`postmaster@dlapiper.com. Thank you.  
`The preceding email message may be confidential or protected by the attorney-client privilege. It is not intended
`for transmission to, or receipt by, any unauthorized persons. If you have received this message in error, please
`(i) do not read it, (ii) reply to the sender that you received the message in error, and (iii) erase or destroy the
`message. Legal advice contained in the preceding message is solely for the benefit of the Foley & Lardner LLP
`client(s) represented by the Firm in the particular matter that is the subject of this message, and may not be
`relied upon by any other party. Internal Revenue Service regulations require that certain types of written advice
`include a disclaimer. To the extent the preceding message contains advice relating to a Federal tax issue, unless
`expressly stated otherwise the advice is not intended or written to be used, and it cannot be used by the recipient
`or any other taxpayer, for the purpose of avoiding Federal tax penalties, and was not written to support the
`promotion or marketing of any transaction or matter discussed herein.  
`Please consider the environment before printing this email.
`
`The information contained in this email may be confidential and/or legally privileged. It has been sent for the sole use of the intended
`recipient(s). If the reader of this message is not an intended recipient, you are hereby notified that any unauthorized review, use, disclosure,
`dissemination, distribution, or copying of this communication, or any of its contents, is strictly prohibited. If you have received this
`communication in error, please reply to the sender and destroy all copies of the message. To contact us directly, send to
`postmaster@dlapiper.com. Thank you.
`
`2